higher-risk mds and aml: how new guidelines are changing diagnosis, classification and management
Published 1 year ago • 2.6K plays • Length 33:29Download video MP4
Download video MP3
Similar videos
-
57:07
higher-risk mds and newly diagnosed aml: what are the latest developments from eha 2022?
-
47:01
advancing the management of mds and aml: novel immune-based approaches
-
1:13:29
understanding higher risk mds and transtion to aml
-
33:55
what’s on the horizon for higher-risk mds? an update on emerging novel agents?
-
10:15
acute myeloid leukemia | clinical presentation
-
29:33
my shocking leukemia diagnosis: “i had no symptoms” | steve buechler’s aml story | the patient story
-
4:41
acute myeloid leukemia survival rate and outlook
-
2:32
how quickly does aml progress? #aml
-
0:48
what is the cause of mds? #aml
-
31:41
advancing the treatment of mds and aml: an update from ash 2021
-
0:48
how do you distinguish between a diagnosis of mds and aml? #aml
-
7:43
understanding the recent who mds classification updates
-
5:17
impact of targeted therapies on treatment of mds and aml
-
20:12
mpn transformation to mds and aml: risk factors, therapy and outcomes
-
3:16
revisions to the icc and who classifications of aml and mds
-
1:00:20
advances in treating high risk mds and aml
-
16:23
venetoclax in higher-risk mds/aml
-
20:58
mpn transformation to mds and aml: risk factors, therapy, and outcomes
-
1:00:54
managing higher risk mdl and aml
-
3:20
comparing the icc and who classifications for secondary aml and their impact on clinical practice
-
1:41
the future of aml and mds diagnosis and treatment
-
5:15
high-risk mds/aml: genomic-driven approaches from ash19 - eytan stein, md